[Treatment with Lenvatinib in a Patient with Hepatocellular Carcinoma and Obstructive Jaundice-A Case Report].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
A 50s male was diagnosed with multiple hepatocellular carcinomas(HCCs), tumor thrombus in the right atrium, and multiple lung metastases. Because the HCCs were unresectable, chemotherapy was planned. However, the patient developed obstructive jaundice 20 days after the first visit, before chemotherapy could be initiated. Immediate treatment was thought necessary to prevent HCC progression. Because the Child-Pugh score was A(6 points)on the first visit, lenvatinib was administered without drainage. The jaundice improved after 10 days of treatment, and computed tomography revealed shrinkage of the HCC and improvement in intrahepatic bile duct dilatation 14 days later. The lenvatinib treatment was continued thereafter, and jaundice did not recur. The patient died 9 months later. This report highlights the usefulness of lenvatinib without drainage in patients with obstructive jaundice due to HCC when urgent treatment is necessary and liver function is well-preserved.